The Growing Demand for
Medical Radioisotopes
Addressing a Critical Supply Gap
As radiopharmaceuticals advance precision oncology and nuclear medicine, entX is developing IsoMedica to support secure, reliable and high-purity medical isotope supply.

OTher Projects
Radiopharmaceuticals are becoming an increasingly important part of precision oncology, creating growing demand for the medical radioisotopes used in advanced cancer therapies and diagnostic procedures.
Around 10,000 hospitals worldwide use medical isotopes, supporting approximately 40 million procedures annually. The global radiopharmaceutical market is also projected to grow significantly, reflecting expanding clinical applications across cancer care, cardiac imaging and chronic disease management.
Reliable Isotope Supply: A Growing Industry Challenge
As demand increases, access to reliable, high-purity radioisotopes remains a critical challenge for the industry.
Medical radioisotopes are the essential payload in many radiopharmaceutical therapies. Without consistent access to these materials, organisations developing new treatments can face significant challenges progressing research, conducting clinical trials and planning commercialisation.
For companies bringing radiopharmaceuticals to market, access alone is not enough. They need dependable supply partners capable of supporting their production requirements and providing confidence in long-term supply.
IsoMedica: Building a Secure Medical Isotope Supply Platform
This supply gap is a key driver behind entX's IsoMedica initiative.
Through IsoMedica, entX is focused on developing a sovereign, secure and reliable medical isotope supply capability to support the growing needs of the nuclear medicine and radiopharmaceutical sectors.
With increasing clinical demand, investment and commercial activity across the industry, establishing dependable isotope supply is essential to supporting the next generation of radiopharmaceutical treatments.
For entX, the opportunity is to address an immediate market need by developing a reliable supply platform that customers can plan around as they progress from research and clinical development towards commercial production.
